Which Neurology Billing Partner in Texas Protects Your Most Valuable Revenue Streams?

The neurology billing partner in Texas that protects your most valuable revenue streams is one built to deliver Novitas Solutions LCD-compliant neurodiagnostic coding, EEG and EMG documentation that survives Medicare Advantage algorithmic review, high-complexity E/M audit defense, and infusion therapy prior authorization management — the four revenue categories where generic medical billing services in Texas consistently fail.

According to AAN benchmarking data, top-performing neurology practices collect 94%–97% of collectible revenue; the specialty average sits 9%–13% below that threshold, representing $400,000–$900,000 in preventable revenue leakage per physician group per 12 months.

Why Texas Makes Neurology Billing Harder Than Most States

Texas presents a uniquely complex neurology billing environment driven by three compounding payer pressures that generalist RCM vendors are structurally unequipped to manage.

Medicare Advantage penetration in Texas exceeds the national average across Houston, Dallas-Fort Worth, San Antonio, and Austin — meaning a disproportionate share of Texas neurology claims flow through MA plans that deploy NLP-based algorithmic review to auto-downcode diagnostic interpretations at 2.4 times the traditional Medicare denial rate.

Texas Medicaid managed care administered through STAR and STAR+PLUS imposes prior authorization requirements on neurodiagnostic procedures, infusion therapies, and specialist referrals that create AR Aging cycles of 50–80 days for groups without dedicated authorization management workflows. And Texas neurology practices fall under Novitas Solutions MAC jurisdiction with specific LCD enforcement on neurological diagnostic procedures that most generalist vendors address with the same reactive appeals process they apply to every other specialty.

The result is compounding payer variance across high-volume payer categories that generic billing vendors absorb as routine write-offs — and that MBC’s Revenue Integrity Framework is specifically engineered to eliminate.

The Triple Threat to Texas Neurology Group Margins:

1. Novitas LCD Non-Compliance on Neurodiagnostic Procedures

EEG (CPT 95816, 95819, 95827), EMG (CPT 95860–95864), and nerve conduction studies (CPT 95907–95913) are among Novitas’s most actively enforced LCD categories. Practices submitting without pre-authorization documentation review average denial rates of 11%–15% on these procedures — translating to $110,000–$180,000 in annual revenue leakage for groups performing 200+ neurodiagnostic studies per month.

2. Infusion Therapy Undercoding and Prior Authorization Failures

MS biologic infusion billing — natalizumab (J2323), ocrelizumab (J2350), ofatumumab (J3061) — requires HCPCS-level precision on dosing units, site-of-service modifiers, and prior authorization compliance that generic RCM vendors cannot reliably produce. Dosing unit miscounts and missing modifiers alone average $85,000–$140,000 in per-12-month revenue loss for practices running active infusion suites.

3. High-Complexity E/M Downcoding Under MDM Documentation Rules

The 2021 AMA E/M MDM revision eliminated time-based coding shortcuts that many Texas neurology practices had relied upon for 99215 capture. Without proactive documentation protocol updates, practices are systematically downcoded from 99215 to 99214 — a $48–$62 loss per visit that compounds to $290,000–$470,000 per 12 months for a high-volume neurology group. Per CMS E/M guidelines, the CPT E/M guidelines for MDM apply to all office/outpatient visits, making proactive documentation audits non-negotiable for high-volume neurology practices.

Neurology Billing Complexity in Texas: Generic RCM vs. MBC

MBC Spotlight: Texas Neurology Revenue Integrity in Practice

MBC’s neurology billing services in Texas operate through a denial root-cause engineering model — not a claims clearinghouse. Every Texas neurology engagement begins with a Complimentary 90-Day AR Diagnostic that maps your current denial distribution by payer, procedure category, and provider, quantifies your recoverable leakage against specialty benchmarks, and builds a payer variance detection protocol calibrated to your Novitas MAC jurisdiction and Texas commercial payer mix.

What the 90-Day AR Diagnostic delivers for Texas neurology groups:

• Novitas LCD gap analysis across EEG, EMG, NCS, and autonomic function testing
• E/M MDM documentation scoring by provider with 99215 capture rate benchmarking
• MS biologic infusion coding audit — HCPCS accuracy, dosing units, prior authorization compliance
• Texas STAR/STAR+PLUS managed care authorization gap identification
• AR Aging stratification by payer with 30% A/R reduction within 90 days recovery pathway

Texas neurology clients average $145,000 in recovered diagnostic and infusion revenue within 90 days — with Novitas LCD compliance reducing EEG and EMG denial rates from 14% to under 4%.

MBC’s system-agnostic platform integrates with your existing EHR — Epic, Athenahealth, NextGen, eClinicalWorks — without requiring migration, and your dedicated account manager maintains provider-level visibility into net realized revenue growth across every payer category.

MBC’s 25+ years of specialty revenue cycle experience and 97% clean claim rate are not averages across general medicine — they reflect performance in high-complexity specialty billing environments where documentation precision and payer-specific protocol compliance determine whether a claim pays or posts as a denial.

Major neurology billing companies operating in Texas include Navicure, R1 RCM, Ensemble Health Partners, and Guidehouse — all enterprise RCM organizations that apply generalist workflows to specialty-specific billing environments. Their scale produces volume throughput; it does not produce Novitas LCD expertise, Texas STAR managed care precision, or infusion therapy HCPCS accuracy at the provider level. MBC’s fee structure is percentage-of-collections with no upfront cost — you pay when collections improve, not before.

Request Your Free Revenue Diagnostic

Texas neurology groups collecting $1M to $5M or more per month are absorbing $400,000–$900,000 in preventable revenue leakage per 12 months — not because of coding volume, but because of Novitas LCD non-compliance, infusion undercoding, and MA diagnostic denials that generic billing workflows treat as acceptable attrition.

MBC’s Strategic Revenue Diagnostic identifies exactly where your neurology revenue is leaking before you make any commitment. Your dedicated account manager delivers a payer-specific recovery roadmap — quantified, actionable, and calibrated to your Texas MAC jurisdiction — at no cost.

Request Your Free Revenue Diagnostic

Related Neurology Billing Resources

• What Is Causing Neurology Claim Denials — Understand the most common denial triggers in neurology billing and how to address them proactively.
• Reduce Denials and Delays in Neurology Billing — Proven strategies to improve clean claim rates and reduce days in AR for neurology practices.
• Best Neurology Billing Companies 2026 — Compare the top neurology billing partners for E/M revenue management and denial reduction.
• Mastering Neurology Billing Guidelines — A complete guide to neurology billing codes, documentation requirements, and payer rules.
• Neurology Billing Services in California — See how MBC’s specialty neurology billing expertise extends to California practices and payer environments.

Frequently Asked Questions

What makes a neurology billing partner in Texas different from a general medical billing service?

A Texas neurology billing partner must deliver Novitas LCD-compliant neurodiagnostic coding, MS biologic infusion billing precision, and high-complexity E/M MDM documentation protocols — the three capabilities where generalist medical billing services in Texas consistently produce 11%–15% denial rates on your highest-dollar procedures.

What Novitas MAC LCD policies most affect Texas neurology billing?

Novitas enforces active LCDs on EEG (L34795), EMG, nerve conduction studies, and autonomic function testing — each requiring pre-submission medical necessity documentation, not post-denial appeals, because the average Novitas appeal cycle recovers less than 60% of denied neurodiagnostic revenue. You can review active CMS Local Coverage Determinations for current Novitas LCD policies.

How does Texas STAR Medicaid affect neurology specialist reimbursement?

Texas STAR and STAR+PLUS MCOs apply managed care-specific prior authorization requirements that result in 12%–18% reimbursement below contractual rates without dedicated MCO follow-up protocols — creating 50–80-day AR Aging cycles for groups without payer variance detection infrastructure.

What infusion therapy billing errors are most common in Texas neurology practices?

Incorrect HCPCS J-code selection for MS biologics — natalizumab (J2323), ocrelizumab (J2350), ofatumumab (J3061) — combined with dosing unit miscounts and missing site-of-service modifiers averages $85,000–$140,000 in revenue leakage per 12 months for active Texas neurology infusion suites.

Does MBC handle Medicare Advantage neurology billing for Texas groups?

Yes — MBC manages Texas Medicare Advantage neurology billing across all major MA plans in Houston, Dallas-Fort Worth, San Antonio, and Austin, with NLP-resistant documentation protocols and diagnostic interpretation appeal workflows that recover 78%–84% of initially denied MA claims within 30 days.